A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.

被引：0
|
作者：
Takahashi, Naoki
Iwasa, Satoru
Tachikawa, Masanori
Fukahori, Masaru
Sudo, Kazuki
Sasaki, Yusuke
Shoji, Hirokazu
Honma, Yoshitaka
Okita, Natsuko
Takashima, Atsuo
Hamaguchi, Tetsuya
Boku, Narikazu
Shimada, Yasuhiro
Yamagiwa, Koki
Ebata, Yuka
Uchida, Yasuo
Honda, Kazufumi
Terasaki, Tetsuya
Yamada, Yasuhide
机构：
[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan
[2] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan
[3] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, Fukuoka, Japan
[4] Natl Canc Ctr, 1-1 Tsukiji 5 chome, Tokyo, Japan
[5] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 chome, Tokyo, Japan
[6] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan
[7] Natl Canc Ctr, Res Inst, Tokyo 104, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.759
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
759
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Naoki Takahashi
    Satoru Iwasa
    Masaru Fukahori
    Kazuki Sudo
    Yusuke Sasaki
    Hirokazu Shoji
    Yoshitaka Honma
    Natsuko Tsuda Okita
    Atsuo Takashima
    Tetsuya Hamaguchi
    Narikazu Boku
    Yasuhiro Shimada
    Kazufumi Honda
    Tesshi Yamada
    Yasuhide Yamada
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 567 - 575
  • [2] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Takahashi, Naoki
    Iwasa, Satoru
    Fukahori, Masaru
    Sudo, Kazuki
    Sasaki, Yusuke
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko Tsuda
    Takashima, Atsuo
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Shimada, Yasuhiro
    Honda, Kazufumi
    Yamada, Tesshi
    Yamada, Yasuhide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 567 - 575
  • [3] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [4] Panitumumab or cetuximab combined with irinotecan in patients with KRAS wild-type metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
    Ikezawa, Nobuaki
    Iwasa, Satoru
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko T.
    Kato, Ken
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [6] ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
    Hayashi, Kaori
    Mitani, Seiichiro
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Sugiyama, Keiji
    Tsushima, Takahiro
    Honda, Kazunori
    Todaka, Akiko
    Masuishi, Toshiki
    Yokota, Tomoya
    Narita, Yukiya
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [9] Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
    Shitara, Kohei
    Yamazaki, Kentaro
    Uetake, Hiroyuki
    Kato, Takeshi
    Oki, Eiji
    Yamanaka, Takeharu
    Ohashl, Yasuo
    Yoshino, Takayukl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Nakajima, Go
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
12345